Tomas Mikal Lind Eagan


Professor, Research group leader for the Bergen Respiratory Research group and Senior Consultant and Section leader for research at the Department of Thoracic Medicine, Haukeland University Hospital



Respiratory Medicine to the medical students at the University of Bergen in MED4, MED5, MED6, MED11 and MED12. 


See a complete overview of publications in Cristin.




The Bergen COPD Microbiome Study (MicroCOPD)

The study aims to characterize the airways microbiome in patients with COPD, compared with healthy adults.

Secondary motives are to assess different bronchoscopic sampling techniques, to compare the microbiome within the lungs (upper versus lower airways, left versus right lung), the stability of the microbiome, and to study the impact of tobacco smoking and composition of the lower airways microbiome on development of COPD.

The pilot study was performed spring of 2012, data collection was performed 213-2015.16Sr DNA sequencing was performed in-house on the Illumina MiSeq platform. Several research papers have been published from this study, and already three bright PhD students (Einar Marius Martinsen, Christine Drengenes and Elise Leiten) have finalized their PhD projects with data from this study. Several more are underway.

The lung microbiome in interstitial lung disease Study (MicroILD)

This is an extension of the MicroCOPD study, with the aim to characterize the airways microbiome in patients undergoing evaluation for interstitial lung diseases. Data collection was performed 2014-2016, and 70 patients with ILDs were included, and papers on IPF and sarcoidosis have been published.

The lung microbiome in lung cancer study (MicroLC)

The final extension of the MicroCOPD study is per August 2023 in its pilot phase. We aim to examine how the pulmonary and gut microbiome influences risk of lung cancer, influence on treatment response and risk of treatment-related side effects.

The Bergen GeneCOPD follow-up study (GenKOLS follow-up)

The first Bergen GeneCOPD study was performed in 2002/04, where 500 COPD patients and healthy controls were assessed with a CT scan, lung function testing and clinical data, and gene wide association studies were performed. In 2014 the follow-up started, aiming to include 250 patients and 400 controls. The primary study question is the assessment of longitudinal change in COPD assessed by CT thorax, secondary motive is to assess risk factors for comorbid coronary heart disease. 

The Bergen COPD Cohort Study (BergenCOPD)

The study started in 2006 and ended in 2014. More than 400 COPD patients and 300 healthy controls were included, and most were attempted followed until the end of 2014, with annual clinical examinations.

The main research question was to search for predictors of later advers outcomes such as mortality, exacerbation frequency, development of cachexia and lung function decline. Almost 40 research papers are published from this study, and data from this study have been part of a number of PhD theses (Louise Persson, Eirunn Waatevik, Bernt Aarli, Bente Frisk, Marie Waatevik, Gunnar Husebø, Solveig Tangedal)